Time filter

Source Type

Moscow, Russia

Pulmonary hypertension (PH) is characterized by a poor prognosis: the three-year survival rate in patients with PH is not greater than 60% as evidenced by current national registries. In the past decade, there have been drugs that are able to relieve symptoms of the disease, to slow down its progression, and improve quality of life. Historically, clinical trials dealing with PH have had a fixed and rather short-tern period and most commonly used the index "the change in the distance covered in the 6-minute walk test" as a primary endpoint. Further optimization of PH therapy requires that the efficacy of drugs and the strategies of therapy be evaluated with respect to their effects on morbidity and mortality, i.e. on prognosis. The SERAPHIN trial is now the only completed and published clinical trial using the combined index of morbidity and mortality as a primary endpoint. It demonstrates that that therapy with the novel drug macitentan causes a reduction in morbidity and mortality in patients with PH. Source

Sochivko D.G.,JSC Syntol | Fedorov A.A.,Russian Academy of Sciences | Varlamov D.A.,All Russia Research Institute of Agricultural Biotechnology | Kurochkin V.E.,Russian Academy of Sciences | Petrov R.V.,Federal Biomedical Agency
Doklady Biochemistry and Biophysics | Year: 2016

The paper reviews different approaches to the mathematical analysis of polymerase chain reaction (PCR) kinetic curves. The basic principles of PCR mathematical analysis are presented. Approximation of PCR kinetic curves and PCR efficiency curves by various functions is described. Several PCR models based on chemical kinetics equations are suggested. Decision criteria for an optimal function to describe PCR efficiency are proposed. © 2016, Pleiades Publishing, Ltd. Source

Kazubskaya T.P.,Nn Blokhin Russian Cancer Research Center | Kozlova V.M.,Nn Blokhin Russian Cancer Research Center | Filippova M.G.,Nn Blokhin Russian Cancer Research Center | Trofimov E.I.,Federal Biomedical Agency | And 5 more authors.
Arkhiv patologii | Year: 2016

UNLABELLED: Familial adenomatous polyposis (FAP) and Peutz-Jeghers syndrome are genetic diseases characterized by gastrointestinal polyps, extraintestinal manifestations, and autosomal dominant inheritance. The carriers of these diseases from early childhood are at risk for neoplasias at different sites, which are symptomatic at various ages.AIM: to study the clinical organ-specific manifestations in patients with FAP and Peutz-Jeghers, genetics update and possibilities of diagnosis, monitoring, and treatment of these diseases.MATERIAL AND METHODS: The authors give the results of their examination and follow-up of children with FAP and Peutz-Jeghers hamartoma-polypous syndrome. In addition, current data from PubMed, Medline (including reviews, original articles and case reports) were used.RESULTS: The main clinical organ-specific signs of multiple tumors in FAP and Peutz-Jeghers syndrome are shown. Data on the assessment of a risk for malignant tumors at various sites in the affected patients and their family members at different ages are provided. Each of these syndromes has a dissimilar genetic foundation. FAP is caused by the germline mutations in the APC gene, Peutz-Jeghers syndrome is by the STK11 gene, which predispose individuals to specifically associated neoplasias and require different follow-up strategies. Information on a phenotype-genotype correlation may serve as a reference point for the possible severity and various manifestations of a disease. An update on the molecular pathogenesis of these diseases is considered.CONCLUSION: Molecular genetic testing of the genes associated with FAP and Peutz-Jeghers syndromes makes it possible to timely recognize family members at high risk, to plan therapeutic strategy and to affect the course of a disease. The joint participation of pediatricians, proctologists, oncologists, morphologists, geneticists, and molecular biologists is essential to timely recognize the carriers of the syndromes and a better prognosis in these patients.Abstract available from the publisher. Source

Kolobov A.V.,Saint Petersburg State University | Musatova E.V.,Saint Petersburg State University | Karev V.E.,Federal Biomedical Agency | Niauri D.A.,Saint Petersburg State University | And 2 more authors.
Arkhiv Patologii | Year: 2014

The paper presents the results of investigating the mechanisms of placental insufficiency and transplacental infection of infants born to HIV-infected mothers who have received specific antiretroviral therapy mothers and who have not. Source

Chuchalin A.G.,Federal Biomedical Agency
Terapevticheskii Arkhiv | Year: 2010

The diffuse alveolar hemorrhage syndrome (DAHS) determines three symptoms: hemoptysis, dyspnea, and anemia. DAHS may occur in the presence of diverse etiological and clinical manifestations of diseases. The paper presents information on the diseases and states, in which DAHS develops in different forms, and data on morphological changes in the lung. It also describes the clinical signs of DAHS, the specific features of its different forms, the methods of laboratory and instrumental diagnosis, as well as methods of its treatment. Source

Discover hidden collaborations